Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Other Non-Current Liabilities (2016 - 2025)

Amicus Therapeutics' Other Non-Current Liabilities history spans 16 years, with the latest figure at $4.2 million for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Liabilities rose 5785.92% year-over-year to $4.2 million, compared with a TTM value of $4.2 million through Dec 2025, up 5785.92%, and an annual FY2025 reading of $4.2 million, up 5785.92% over the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $4.2 million at Amicus Therapeutics, down from $8.6 million in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $27.3 million in Q2 2021, with the low at $71000.0 in Q4 2023.
  • Average Other Non-Current Liabilities over 5 years is $12.2 million, with a median of $10.9 million recorded in 2023.
  • Year-over-year, Other Non-Current Liabilities plummeted 99.67% in 2023 and then soared 12078.87% in 2025.
  • Tracing FOLD's Other Non-Current Liabilities over 5 years: stood at $20.3 million in 2021, then grew by 5.3% to $21.4 million in 2022, then plummeted by 99.67% to $71000.0 in 2023, then changed by 0.0% to $71000.0 in 2024, then soared by 5785.92% to $4.2 million in 2025.
  • Per Business Quant, the three most recent readings for FOLD's Other Non-Current Liabilities are $4.2 million (Q4 2025), $8.6 million (Q2 2025), and $71000.0 (Q4 2024).